Disclosures

Jeremy S. Abramson, MD, MMSc

Director, Jon and Jo Ann Hagler Center for Lymphoma, Massachusetts General Hospital;
Associate Professor of Medicine, Harvard Medical School, Boston

Received clinical research support from or served on data safety monitoring board for AbbVie, BeiGene, Bristol Myers Squibb, Cellectis, Genentech, Merck & Co., Mustang bio, and Regeneron Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for AbbVie, AstraZeneca, Bristol Myers Squibb, Foresight Diagnostics, Genentech, and Novartis

William J. Gradishar, MD, FACP, FASCO

Betty Bramsen Professor of Breast Oncology and Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support from or served on data safety monitoring board for Carrick, Eli Lilly and Company, Gilead Sciences, Greenwich LifeSciences, Novartis, and Stemline Therapeutics

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca and Merck & Co

Joyce C. Liu, MD, MPH

Associate Chief, Division of Gynecologic Oncology;
Associate Professor of Medicine, Harvard Medical School, Boston

Received clinical research support from or served on data safety monitoring board for Aravive, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Genentech, GSK, Impact Therapeutics, Pfizer, Regeneron Pharmaceuticals, SeaGen, SystImmune, Volastra, and Zentalis Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca, Bristol Myers Squibb, Daiichi-Sankyo, Deciphera Pharmaceuticals, Eisai, Genentech, GSK, LoxoLilly, and Zentalis Pharmaceuticals

Soo Park, MD

Associate Professor, Division of Hematology/Oncology, UC San Diego Moores Cancer Center,
San Diego, California

Received clinical research support/data safety monitoring board from Bristol Myers Squibb, Merck & Co., Regeneron Pharmaceuticals, and Replimune

Served on scientific advisory board or as a consultant or expert witness for Regeneron Pharmaceuticals and Replimune

Gregory J. Riely, MD, PhD

Vice Chair of Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer Center,
New York, New York

Received clinical research support/data safety monitoring board from Amgen, Chugai, Eli Lilly and Company, Genentech, Merck & Co., Mirati, Novartis Pharmaceuticals, Pfizer, and Takeda Pharmaceuticals North America

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca, Bayer HealthCare, Bristol Myers Squibb, ERASCA, Merck & Co., Mirati, Novartis Pharmaceuticals, and Pfizer

Medical Writers:

The following medical writers reported no conflicts of interest.

Jenna Carter, PhD; Vanessa A. Carter, BS; Celeste L. Dixon; Julia Cipriano, MS; Joseph Cupolo, MS; Bryna Goeking; Justine Landin, PhD; Victoria Kuhr, MS; Amy MacDonald, MS; Joshua Madera, MD; Margie Miller; Julian Anna Nowogrodzki; Susan Reckling, MA; Amanda E. Ruffino, BA; Chris Schimpf, MSW